Published in J Clin Oncol on December 22, 2003
Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol (2003) 1.74
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem (2007) 3.24
AGEMAP: a gene expression database for aging in mice. PLoS Genet (2007) 3.22
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol (2002) 3.05
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol (2009) 2.97
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol (2008) 2.88
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87
Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol (2010) 2.83
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet (2009) 2.58
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov (2012) 2.48
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res (2012) 2.31
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res (2007) 2.28
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov (2012) 2.27
Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer (2003) 2.23
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol (2012) 2.21
The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol (2005) 2.12
Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol (2008) 2.11
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol (2005) 2.07
Chemotherapy for metastatic melanoma: time for a change? Cancer (2007) 1.99
Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol (2012) 1.92
Ghrelin promotes thymopoiesis during aging. J Clin Invest (2007) 1.83
12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep (2012) 1.81
Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell (2003) 1.81
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol (2013) 1.77
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer (2006) 1.75
Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother (2012) 1.68
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res (2013) 1.66
A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer (2011) 1.66
The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer (2007) 1.64
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol (2008) 1.61
Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol (2002) 1.57
Multimodality management of desmoid tumors: how important is a negative surgical margin? J Surg Oncol (2008) 1.55
Interferon alfa-2a for melanoma metastases. Lancet (2002) 1.55
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov (2013) 1.52
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res (2004) 1.51
Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer (2004) 1.50
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol (2003) 1.49
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother (2013) 1.48
Melanoma--an unlikely poster child for personalized cancer therapy. N Engl J Med (2010) 1.47
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation. Pigment Cell Melanoma Res (2009) 1.45
Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist (2003) 1.42
Proper margins of excision in dermatofibrosarcoma protuberans: wide or narrow? Ann Surg Oncol (2008) 1.42
Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res (2008) 1.41
Lymphangiogenesis: host and tumor factors in nodal metastasis. Arch Dermatol (2008) 1.38
Sunlight and reduced risk of cancer: is the real story vitamin D? J Natl Cancer Inst (2005) 1.37
Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res (2009) 1.36
Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. Clin Vaccine Immunol (2011) 1.35
Lymphatic mapping and sentinel lymph node biopsy in the detection of early metastasis from sweat gland carcinoma. Cancer (2003) 1.35
Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol (2010) 1.35
Wnt5A activates the calpain-mediated cleavage of filamin A. J Invest Dermatol (2009) 1.32
CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann Surg Oncol (2008) 1.28
SAGE identification and fluorescence imaging analysis of genes and transcripts in melanomas and precursor lesions. Cancer Biol Ther (2004) 1.24
Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer (2003) 1.24
Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer (2013) 1.23
Ipilimumab. Nat Rev Drug Discov (2011) 1.20
Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt. Pigment Cell Melanoma Res (2009) 1.19
Retracted Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int (2005) 1.18
Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys (2011) 1.17
Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma. Cancer Control (2009) 1.15
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol (2002) 1.15
Transcriptome analysis of age-, gender- and diet-associated changes in murine thymus. Cell Immunol (2007) 1.14
New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res (2011) 1.12
Conjunctival melanomas harbor BRAF and NRAS mutations--Letter. Clin Cancer Res (2013) 1.10
Retroperitoneal sarcomas. Cancer Imaging (2005) 1.09
Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol (2013) 1.09
RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res (2012) 1.09
PKC and PKA phosphorylation affect the subcellular localization of claudin-1 in melanoma cells. Int J Med Sci (2009) 1.08
c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol (2009) 1.08
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res (2007) 1.07
Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma. Int J Radiat Oncol Biol Phys (2007) 1.07
Point: Interferon-alpha for adjuvant therapy for melanoma patients. J Natl Compr Canc Netw (2004) 1.06
Update on the targeted therapy of melanoma. Curr Treat Options Oncol (2013) 1.06